MedXPrime


About MedXPrime



The era of ‘Personalized Medicine’ has now arrived. It allows your physician to understand from your specific DNA profile what medications will work best. It’s called ‘pharmacogenetic testing’ or PGT. No more trial and error prescribing, no longer having the danger of Adverse Drug Reactions (ADRs) which put over 2 million people annually in the hospital and cause over 100,000 deaths each year. Now doctors can have the knowledge to avoid these issues. Personalized Medicine helps doctors to individualize drug therapy, decrease adverse drug reactions, and increase the effectiveness of treatment plans. In other words:


“Right Information, Right Drug, Right Dose, Right from the beginning”

According to Felix Frueh, Associate Director of FDA, Personalized Medicine “is the science that allows us to predict a response to drugs based on an individuals’ complete genetic makeup.”


Several U.S. medical facilities have now adopted phamacogenetic testing:


  • Vanderbilt University Medical Centre
  • John Hopkins
  • Mayo Clinic
  • Duke Medical Centre
  • RCIVA Dallas (Cardiovascular & Interventional Vascular Associates)
  • HCA (Hospital Corporation of America)

The AMA calls it "The Future of Medicine"


Vanderbilt calls it "Personalized Medicine"


Cornell/Columbia calls it "Precision Prescribing"


Eli Lilly calls it "Tailored Therapuetics"


If you are concerned about the effect that your medications are having on each other and want to dramatically reduce the possibility of an ADR; if you want to get the best result from your drug therapy as soon as possible, then you must speak with your health care provider about PGT.


Why should physicians test their patients? Very simply, it’s the right thing to do:


  • Eliminate trial and error.

  • Eliminate “One Size Fits All” medication management.

  • Enhance Patient Care.

  • Enhance Patient Satisfaction.

  • Enhance Compliance.

  • Enhance Patient Confidence.

  • Risk Management: 

    Reduces liability to physicians


We are all different! We have different DNA and respond differently to medications. Only 70% of Caucasians metabolize normally (the reason why many drug studies are performed in northern Europe). Some 40% of African Americans, 50% of Asians and 80% of Polynesians do NOT metabolize normally! Out of 100 patients in a waiting room, only 46% metabolize normally while 35% are intermediate, 13% are poor and 6% are ultrarapid metabolizers.


The PGT test saves the "trial and error" process and the associated costs from ADRs. It gives actionable data to the physician so the right medication at the right dose will be prescribed the first time to achieve the desired therapeutic results. As an example, the FDA has "black boxed" Plavix. Patients with reduced-function alleles have a 3.5-8 times greater risk for major adverse cardiovascular events. This can be prevented by simply ordering the test for each patient. There is no way of knowing how each patient will react to Plavix and there is a huge legal implication if a physician does not order the test.


The advantages of personalized medicine are:


  • develop better efficacy of treatment, quicker response

  • better outcomes

  • fewer adverse events, and

  • lower health care systemic costs


Pharmacogenetic testing (PGT) detects single nucleotide polymorphism of nine cytochrome P450 enzymes in the liver: CYP2D6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, Factor II, Factor V, MTHFR, VKROC1.


By identifying the genotypes of these enzymes we can predict an individual's ability to metabolize about 95% of all medications. The phenotypes are assigned based on the patient's metabolizing ability as poor, intermediate, intermediate-extensive, extensive, and ultra-rapid metabolizers. Armed with the genetic information, physicians can provide personalized care by delivering the right medication at the right dosage to the right patient. In addition, PGT can help reduce adverse drug reactions, avoid drug interactions, prevent overdose and death, and save precious time and medical costs. The test is a simple non-invasive, buccal cell-based cheek swab. The PGT has a short turn-around time and easy to read lab reports. Individuals who may benefit from PGT include patients with abnormally high or low metabolite to substrate ratios in urine drug screening, patients with multiple organ system issues or on multiple medications, patients who suffer from debilitating adverse drug reactions, and patients who have gone through sequential ineffective drug trials. PGT is proven a useful tool in chronic pain management where the use of narcotics and other medication is likely.


According to the FDA, adverse drug reactions cause over 2 million hospitalizations per year and 106,000 annual deaths, while contributing $136 billion dollars to annual health care costs in our country. These are terrible statistics but the worst part is they are largely avoidable. The best part is that the technology is now available to every physician to ensure patient safety and the best possible treatment plan.


Contact your MedXPrime Associate for more information and get tested now!